Cyclin-dependent kinase-mediated phosphorylation of breast cancer metastasis suppressor 1 (BRMS1) affects cell...

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Breast Cancer Metastasis Suppressor 1 (BRMS1) inhibits metastasis in various cancers by interacting with the mSin3/histone deacetylase (HDAC) transcriptional repressor complex.
• The precise mechanisms by which BRMS1 regulates metastasis are not fully understood, particularly regarding post-translational modifications.

Purpose of the Study:

• To investigate the role of Cyclin-Dependent Kinase 2 (CDK2) in the regulation of BRMS1.
• To determine the functional consequences of BRMS1 phosphorylation by CDK2 on metastasis suppression, cell cycle progression, and transcriptional activity.

Main Methods:

• BRMS1 was identified as a substrate of CDK2, with phosphorylation occurring at serine 237 (S237).
• Site-directed mutagenesis was used to create a non-phosphorylatable BRMS1 mutant (S237A).
• Cell proliferation, cell cycle progression, migration assays, and co-immunoprecipitation were performed using MDA-MB-231 breast cancer cells expressing wild-type or mutant BRMS1.

Main Results:

• Phosphorylation of BRMS1 at S237 by CDK2 was confirmed.
• Mutation of S237 did not affect cell cycle progression or proliferation of MDA-MB-231 cells.
• However, mutation of S237 significantly affected the migration of these breast cancer cells.
• BRMS1 phosphorylation did not alter its binding to the mSin3/HDAC complex or its transcriptional repressor activity.
• Phosphorylation did not affect BRMS1's subcellular localization, despite S237 being near a nuclear localization sequence.

Conclusions:

• CDK2-mediated phosphorylation of BRMS1 at S237 is a novel regulatory mechanism.
• This phosphorylation event specifically regulates tumor cell migration, a key aspect of metastasis.
• BRMS1 phosphorylation by CDK2 represents a potential therapeutic target for controlling breast cancer metastasis.